Video

Dr. Secord on Understanding Patient Preferences

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the importance of understanding patient preferences regarding treatment regimens.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the importance of understanding patient preferences regarding treatment regimens.

If practitioners do not understand their patients’ goals for therapy, then they may not be delivering patients the best regimen, Secord says. While some patients deem survival the most important factor of their therapy, others may place quality of life higher on the list. Therefore, practitioners could possibly provide patients with a more toxic regimen that does not improve their survival in a clinically meaningful way, if they do not take their preferences into account.

What a physician thinks is an overly toxic regimen may not be the equivalent of what a patient believes is overly toxic, Secord explains. For example, one patient may be willing to accept severe toxicity in order to obtain additional time of living longer without disease, while some patients may not be able to tolerate any amount of toxicity.

As an example, Secord describes a patient who is an artist and soccer player with a preference to avoid therapy with neurotoxicity, since it will dramatically affect her livelihood and regular activities.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD